ATE298575T1 - Verwendung von 1,4-benzothiazepinderivaten als medikamente zur überwindung der toleranz für carcinostatika - Google Patents

Verwendung von 1,4-benzothiazepinderivaten als medikamente zur überwindung der toleranz für carcinostatika

Info

Publication number
ATE298575T1
ATE298575T1 AT00929801T AT00929801T ATE298575T1 AT E298575 T1 ATE298575 T1 AT E298575T1 AT 00929801 T AT00929801 T AT 00929801T AT 00929801 T AT00929801 T AT 00929801T AT E298575 T1 ATE298575 T1 AT E298575T1
Authority
AT
Austria
Prior art keywords
drugs
anticancer
resistance
anticancer drugs
carcinostatics
Prior art date
Application number
AT00929801T
Other languages
English (en)
Inventor
Noboru Kaneko
Kazuhito Nishio
Takashi Nakamura
Original Assignee
Noboru Kaneko
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noboru Kaneko filed Critical Noboru Kaneko
Application granted granted Critical
Publication of ATE298575T1 publication Critical patent/ATE298575T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT00929801T 1999-05-19 2000-05-19 Verwendung von 1,4-benzothiazepinderivaten als medikamente zur überwindung der toleranz für carcinostatika ATE298575T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13919699 1999-05-19
PCT/JP2000/003216 WO2000071132A1 (en) 1999-05-19 2000-05-19 Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance

Publications (1)

Publication Number Publication Date
ATE298575T1 true ATE298575T1 (de) 2005-07-15

Family

ID=15239803

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00929801T ATE298575T1 (de) 1999-05-19 2000-05-19 Verwendung von 1,4-benzothiazepinderivaten als medikamente zur überwindung der toleranz für carcinostatika

Country Status (12)

Country Link
US (1) US6977252B1 (de)
EP (1) EP1184037B1 (de)
KR (1) KR100686617B1 (de)
CN (1) CN1178663C (de)
AT (1) ATE298575T1 (de)
AU (1) AU774656B2 (de)
CA (1) CA2373484C (de)
DE (1) DE60021075T2 (de)
NO (1) NO20015600L (de)
TW (1) TWI221093B (de)
WO (1) WO2000071132A1 (de)
ZA (1) ZA200109334B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ1ライアノジン受容体に基づく方法
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
CN106795148B (zh) 2014-07-30 2019-12-10 埃塔斯制药株式会社 1,4-苯并硫氮杂*-1-氧化物衍生物的光学异构体及使用它的医药组合物
KR102440098B1 (ko) * 2020-07-31 2022-09-05 부산대학교 산학협력단 Agr2의 동종이량체를 표적으로 하는 저분자 화합물을 유효성분으로 함유하는 암 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS579712A (en) * 1980-06-20 1982-01-19 Fukumi Morishige Instilling (dripping) liquid for intravenous injection
JP2703408B2 (ja) * 1990-12-28 1998-01-26 麒麟麦酒株式会社 1,4‐ベンゾチアゼピン誘導体
JP3093419B2 (ja) 1992-03-30 2000-10-03 麒麟麦酒株式会社 1,4‐ベンゾチアゼピン誘導体
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5700826A (en) 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
JP4063964B2 (ja) 1998-08-12 2008-03-19 金子 昇 神経細胞保護薬

Also Published As

Publication number Publication date
DE60021075T2 (de) 2006-05-24
NO20015600D0 (no) 2001-11-16
ZA200109334B (en) 2003-01-29
US6977252B1 (en) 2005-12-20
EP1184037B1 (de) 2005-06-29
WO2000071132A1 (en) 2000-11-30
KR20020008407A (ko) 2002-01-30
CN1361693A (zh) 2002-07-31
NO20015600L (no) 2001-12-20
CN1178663C (zh) 2004-12-08
KR100686617B1 (ko) 2007-02-23
CA2373484A1 (en) 2000-11-30
AU4778300A (en) 2000-12-12
AU774656B2 (en) 2004-07-01
DE60021075D1 (de) 2005-08-04
EP1184037A4 (de) 2003-12-03
TWI221093B (en) 2004-09-21
EP1184037A1 (de) 2002-03-06
CA2373484C (en) 2009-01-20

Similar Documents

Publication Publication Date Title
ATE298575T1 (de) Verwendung von 1,4-benzothiazepinderivaten als medikamente zur überwindung der toleranz für carcinostatika
ATE327230T1 (de) Piperidinverbindungen und diese enthaltenden medikamente
BR9910122A (pt) Compostos amidina
NO324249B1 (no) Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater til fremstilling av derivatene
KR960004344A (ko) 6원 질소 함유 헤테로아릴-옥사졸리디논
ES2164241T3 (es) Compuestos pentaciclicos.
IL154709A0 (en) Pyridazinone and triazinone derivatives and pharmaceutical compositions containing the same
BRPI0414573A (pt) 7-amino alquilidenil-quinolonas e naftiridonas heterocìclicas
ATE271045T1 (de) Sauerstoffhaltige heterocyclische verbindungen
BR0308207A (pt) Derivado de arilamidina ou um sal do mesmo, composto, e, agente antifúngico
ATE513821T1 (de) Thiadiazolin-derivate zur behandlung von krebs
DE60207796D1 (de) Electrochrome Lösung, enthaltend eine Hydrazonverbindung und mit dieser hergestellte Vorrichtung
DE69208400D1 (de) Mono- und Bis-Alkylaminoanthracycline
BRPI0507289A (pt) derivados de pirrolo pirimidina úteis para tratamento de doenças proliferativas
BR0003941A (pt) Compostos pirimidina-2,4,6-triona
ATE234315T1 (de) Medikamente gegen trhombocytopenie
ATE493988T1 (de) Pyrimidinderivate enthaltendes medikament
ATE259790T1 (de) Substituierte tetrahydropyrimidin derative und ihre verwendung als polymerization hemmer für vinyl aromatische verbindungen
ATE318265T1 (de) Amidin-derivate, ihre herstellung und verwendung als medikamenten
KR910700252A (ko) 디아자비시클로알칸 유도체
RU2006132901A (ru) Лекарственное средство на основе производных 4-замещенных-3-(3-диалкиламинометил-индол-1-ил)малеимидов
TH41647A3 (th) สารฆ่าวัชพืชชนิดใหม่
TH41540A (th) อนุพันธ์ของคาร์โบสไทริล

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties